A federally funded survey of older adults reports surprising day-of use, common medical motivations, and preferred THC delivery methods—data clinicians and DMV families should note.

Marijuana Moment reports a Texas Senate candidate’s alcohol-linked cash haul while opposing cannabis reform—plus new research on teen use and clinical science DMVers should track.

Marijuana Venture spotlights Chris Violas in its 40 Under 40. We examine how tech‑minded leadership can shape patient delivery services, science‑based safeguards, and DMV implications.

State health officials pulled back proposed fee increases for Oregon’s supervised psilocybin program after broad backlash, but funding questions and possible tax changes remain.

Federal health officials and clinical experts met in Silver Spring to establish safety, credentialing, and access standards for psychedelic medicines.

Gov. Maura Healey files a budget provision allowing veterans with qualifying VA diagnoses to join state medical programs without secondary physician sign-offs.

Federal lobbying hit record highs in Q2 2026 while the DEA targets tryptamines and Oregon reconsiders psilocybin program fees.

Exploring how shared mushroom experiences foster deep human connection amidst evolving drug policy across the DMV region.

Learn how survivor-built vetting frameworks use color-coded flags to help consumers identify ethical guides and avoid abuse.

Estrogen’s influence on serotonin and glutamate links women’s health to psychedelic care. Here’s what patients and DMV providers should understand now.

Psychedelic Alpha has introduced The Psychedelic News Feed Podcast, creating a new way to follow psychedelics developments. Here’s why DMV readers should care.

UMIYAC leaders travel to Spain to affirm that ayahuasca and other Amazonian medicines cannot be detached from the lands, peoples, and spiritual laws that sustain them.

Psychedelic Alpha reports that Resilient has resubmitted its MDMA-for-PTSD application two years after a prior rejection. Here’s what to watch, timelines, and DMV impacts.

Definium Therapeutics reports another positive Phase 3 readout for DT120 in generalised anxiety disorder, with randomized data from the Panorama study now toplined.

A little-known 1969 cannabis journal argued the core points the DEA just made on rescheduling—raising new stakes for patients, researchers, and the DMV in 2026.

DEA issued a scheduling order for five tryptamines as FDA momentum grows, including breakthrough status for a 4‑OH‑DiPT drug candidate aimed at postpartum depression.

After public feedback, Oregon’s health regulators shelved a proposal to double psilocybin licensing fees and will restart rulemaking, with other changes eyed for 2027.

Maine’s cannabis regulator is distributing 12,000 free lockable storage bags through 140 retailers and caregivers, more than doubling last year’s pilot and prioritizing youth and pet safety.

As 5‑MeO‑DMT draws buzz, scientists and conservationists warn against “toad milking.” Here’s what’s known, what’s not, and how DMV readers should approach it.

Bipartisan federal moves and a new Louisiana pilot are reshaping psychedelic therapy research. Here’s how it intersects with dc cannabis research, patient access, and safety.